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Abstract
Background: Hepatitis B virus is one of the most causative agents of human liver disease, including acute and
chronic hepatitis, cirrhosis and hepatocellular carcinoma. The disease is a great health problem worldwide, with
estimated of 350 million chronically infected people. Objective: The aim of this study was to determine the
prevalence of hepatitis B virus in Tefera Hailu Memorial Hospital (THMH) for the last three years (2013, 2014, 2015) by
using secondary data.
Method: A three year retrospective record review was conducted from March 01/2015-July 30/2015. All registered data
for hepatitis B virus serological screening of the specified period were included. The data were collected by predesigned
data collection sheet. The sample size was calculated by simple statistical estimation to be 149 for each year.
Result: Of 482 subjects, 215 (44.60 %) were females and 267 (55.40 %) were males. The overall prevalence of HBV was
102 (21.16 %). The positivity rate was 69 (14.31 %) in the age group between 15 and 45. There was a decrease in the
prevalence of HBV from 2012 up to 2014.
Conclusion: The seroprevalence of HBsAg was higher in males than in females and the yearly prevalence decreases
from 2012–2014. But HBV infection is still a public health problem in Ethiopia. Therefore intensification of health
education concerning modes of transmission and prevention of HBV, early case finding and treatment is recommended
to reduce the spread of the disease.
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Background
Hepatitis B is caused by the hepatitis B virus (HBV), an
envelope, double stranded, circular DNA genome and
classified within the family Hepadnaviridae. It infects the
liver and causes an inflammation called hepatitis, origin-
ally known as serum hepatitis. HBV infection can cause
acute or chronic illness. The acute illness causes liver in-
flammation, vomiting, Jaundice and often death. Chronic
HBV infection may eventually cause liver cirrhosis and
cancer [1–3]. HBV is transmitted parenterally via appar-
ent percutaneous or permucosal exposure to infected
blood or other body fluids [4]. In low prevalence areas,
HBV is typically a disease of young adults who acquire
the infection via mainly unprotected sexual contact or
sharing syringes with HBsAg positive people and
through exposure to contaminated equipment. In high
prevalence regions, most infection occurs prenatally or
during early childhood [5].
However, an estimated 3 % to 5 % adults and up to 95 %
of children develop chronic HBV infection. Persistent in-
fection can also be either symptomatic or asymptomatic;
those with elevated liver chemistries and abnormal biop-
sies are termed as having chronic hepatitis B and those
with normal studies are labeled as chronic HBV carriers.
Long term infection increases risk of developing cirrhosis
and Hepatocellular carcinoma [6]. Although replication
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takes place in the liver, the virus spreads to the blood
where the virus specific proteins and their corresponding
antibodies are found. In infected people blood tests for
these proteins and antibodies are used to diagnose the in-
fection [7]. In chronic hepatitis B, the survivals are esti-
mated to be 100 % at 5 years. However, cirrhosis and
hematoma are two major long term complications of
chronic HBV infection that significantly increase morbid-
ity and mortality [8].
Hepatitis B virus infection remains a major global pub-
lic health problem. Globally, of the two billion people
previously infected, more than 350 million people have
developed chronic HBV infection, causing one million
HBV related deaths each year [9]. Infection with HBV is
highest among developing countries of Asia, Africa, and
pacific Islands and lowest among the developed coun-
tries or America, Europe and Austria [10]. The majority
of chronic carriers of HBV are found in South East Asia
and sub-Saharan Africa [11]. Persistence of such HBV
infection can lead to chronic hepatitis, cirrhosis and
Hepatocellular carcinoma (HCC) [12]. Thus, HBV is a
major health problem in developing countries [13, 14].
Infection with HBV is endemic and causes a great
public health problem in Africa. In Nigeria for example,
66 % of the population had one or more serological
markers of HBV and 9.1 % of them are carriers of
HBsAg [15]. In Ethiopia, the overall prevalence of HBV
varies from 4.7–16.8 % for HBsAg and 70–76.4 % for at
least one marker positive [16]. Similarly a study con-
ducted at JUSH reported a prevalence of 8.2 % [17], indi-
cating HBV infection is of great public health significance
in the nation.
HBsAg prevalence among Vietnamese immigrants and
refugees in several studies was 10.0 – 16.6 % [18, 19]
which reflects 7.4 % for female in the northern territory
and 5.7 % for males and 10.0 for females in South
Australia. Health care workers are about 20 times more
likely to contract the virus than the general public
[19–21]. Blood donors were tested in Pakistan for
HBsAg and HBV DNA and, 3.41 % were positive for
HBsAg by immunochromatographic test, 2.05 % by
ELISA and 1.85 % by PCR [22].
In another study conducted in Ethiopia, 72 % were found
to have evidence of past or present infection of HBV [23].
Another cross sectional study among healthy blood donors
at JUSH showed overall prevalence 24.2 % [24].
In General, hepatitis B virus (HBV) infection and its
squelae (cirrhosis and liver cancer) are major global
health problems mostly in developing countries includ-
ing Ethiopia. As already indicated above, the national
prevalence of HBsAg is as high as 16 %. Therefore, the
aim of this study was to assess the seroprevalence of
HBV for the last three years using laboratory recorded
data (log book) to fill the existing epidemiologic gap in
the area. Moreover, the finding will be used to plan
intervention strategies and can serve as baseline infor-
mation for those who seek to conduct similar studies in
the same area or other parts of the country.
Methods
Study area
The study was conducted at Tefera Hailu’ Memorial
Hospital (THMH) which is located 720 km away from
Addis Ababa, the capital city of Ethiopia. Its local
temperature is 25–34 °C. The people’s native language is
‘Himra/Agew’ and can speak ‘Amharic’ and ‘Tigrigna’.
Currently it is the only hospital in the area giving service
to about 521, 127 population in the zone of which 258,
755 are males and the rest 262, 372 are females [25]. On
average, there were around 36 thousand annual visits
out of which approximately 160 HBsAg tests were or-
dered per year.
Study design and period
A retrospective record review of the laboratory logbook
was conducted from March 01/2015-July 30/2015.
Population
All patients visited THMH from January 2012 to Dec
2014 were target and All patients who were screened for
HBV and registered in the log book from January 2012-
Decemeber 2014 were included in the study.
Laboratory setttings
HBsAg was ordered as part of the antenatal care panel
and for clinical suspicion of liver disease, that is why the
prevalence is high. The Wondfo One Step Cassette Style
HBsAg test kit (Guangzhou Wondfo Biotech Co. Ltd,





Positive Negative Total Positive Negative Total Positive Negative
0–14 2 (1.0 %) 12 (6.1 %) 14 (7.1 %) 1 (0.5 %) 4 (2.0 %) 5 (2.5 %) 3 (1.5 %) 16 (8.1 %) 19 (9.6 %)
15-45 25 (12.6 %) 54 (27.3 %) 79 (39.9 %) 15 (7.6 %) 43 (21.7 %) 58 (29.3 %) 40 (20.2 %) 97 (49.0 %) 137 (69.2 %)
>45 11 (5.6 %) 17 (8.6 %) 28 (14.1 %) 7 (3.5 %) 7 (3.5 %) 14 (7.1 %) 18 (9.1 %) 24 (12.1 %) 42 (21.2 %)
Total 38 (19.2 %) 83 (41.9 %) 121 (61.1 %) 23 (11.6 %) 54 (27.3 %) 77 (38.9 %) 61 (30.8 %) 137 (69.2 %) 198 (100 %)
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China) was being used throughout the study period. The
HBsAg test utilized is a One Step Cassette Style which is
a rapid, direct binding test for the visual detection of
hepatitis B surface antigen (HBsAg) in serum. It is based
on the principle of sandwich immunoassay for determin-
ation of HBsAg in serum.
Sampling method
The national prevalence, 10.8 % was considered for sam-









n = the minimum sample size Zα/2 = 1.966 at 95 %
confidence interval
d = margin of error assumed to be (0.05) P = National
prevalence rate (10.8 %)
Then:
n ¼ 1:966ð Þ
2 0:108 1−0:108ð Þ
0:052
n = 148.9/each year (2012, 2013, 2014)
Even though the minimum sample size was calculated
as149/year, to include all patients who visited the
hospital during the specified period (January 2012 to
Dec 2014) it was elevated to a total of 482.
Data collection and quality control
A checklist was used to collect data on the status of
HBV, age and sex. To ensure the quality of data, the re-
quired data was collected from the laboratory log book
with due attention to avoid any redundancy. Complete-
ness of the checklist was being asserted through periodic
checking.
Data processing and analysis
The collected date was analyzed using Microsoft Excell
following proper entry and cleaning. The result was
presented by percentages and explanations using tables
and figures.
Ethical consideration
Written ethical approval was obtained from the research
community and ethical review committee of Mekelle
University, College of Health Sciences. Moreover, per-
mission was obtained from the Hospital Medical dir-
ector office.
Results
A total of 482 HBsAg rapid test records in the laboratory
log book were included in this study. Among the 482
study subjects, 215 (44.60 %) were females and 267
(55.40 %) were males.
In 2012, 198 subjects were examined using a marker
of HBsAg. 77/198 (38.9 %) were females and 121/198
(61.1 %) were males. In this year, 61/198 (30.8 %) were
sero-positive for HBV. The majority of the patients who
visited the hospital for HBV screening were in the 15 to
45 age group. Likewise the sero-prevalence of HBV was
also higher among this group, 40/198 (20.2 %). With re-
gard to sex, HBV infection was higher in males com-
pared to females, 38/198 (19.2 %) and 23/198 (11.6 %)
respectively (Table 1).
In 2013,134 patients were examined. 58 (43.28 %) were
females and 76 (56.71 %) were males. Among the total





Positive Negative Total Positive Negative Total Positive Negative
0–14 2 (1.5 %) 11 (8.2 %) 13 (9.7 %) 3 (2.2 %) 5 (3.7 %) 8 (6.0 %) 5 (3.7 %) 16 (11.9 %) 21 (15.7 %)
15-45 12 (8.9 %) 36 (26.9 %) 48 (35.8 %) 8 (6.0 %) 32 (23.9 %) 40 (29.8 %) 20 (14.93 %) 68 (50.7 %) 88 (65.7 %)
>45 1 (0.7 %) 14 (10.4 %) 15 (11.2 %) 0 (0) 10 (7.5 %) 10 (7.5 %) 1 (0.7 %) 24 (17.9 %) 25 (18.7 %)
Total 15 (11.2 %) 61 (45.5 %) 76 (56.7 %) 11 (8.2 %) 47 (35.1 %) 58 (43.3 %) 26 (19.40 %) 108 (80.6 %) 134 (100 %)





Positive Negative Total Positive Negative Total Positive Negative
0–14 3 (2 %) 11 (7.3 %) 14 (9.3 %) 0 (0) 5 (3.3 %) 5 (3.3 %) 3 (2 %) 16 (10.7 %) 19 (12.7 %)
15-45 3 (2 %) 30 (20 %) 33 (22 %) 6 (6 %) 63 (42 %) 69 (46 %) 9 (6 %) 93 (62 %) 102 (68 %)
>45 2 (1.33 %) −2114 % 23 (15.3 %) 1 (0.7 %) 5 (3.3 %) 6 (4 %) 3 (2 %) 26 (17.3 %) 29 (19.3 %)
Total 8 (5.3 %) 62 (41.3 %) 70 (46.7 %) 7 (4.7 %) 73 (48.7 %) 80 (53.3 %) 15 (10 %) 135 (90 %) 150 (100 %)
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134 subjects, 26 (19.40 %) tested positive and the
remaining 108 (80.60 %) were negative for HBV. The
prevalence of HBV in males was higher than females, 15
(11.19 %) and 11 (8.21 %) respectively (Table 2).
In 2014, 150 subjects were screened. 80 (53.33 %) were
females and 70 (46.67 %) were males. Only 15 /150
(10 %) of them were found to be seropositive for HBsAg.
As in the previous years, the prevalence of HBV in males
was higher than females, 7 (4.67 %) and 8 (5.33 %) re-
spectively (Table 3).
The overall sero-prevalence of HBsAg in the years
2012 to 2014 was 21.2 %. The sero-prevalence in males
was higher than in females, 22.8 % and 19.1 % respect-
ively. Out of the HBV infected patients, 59.8 % were
males and 40.2 % were females (Table 4).
Regarding the age of the study subjects in all years of
study, 67.8 % were in the age group of 15-45 years.
Moreover the sero-prevalence of HBV was also compara-
tively higher among this age group, 14.3 % (Table 5).
There is a general decrease in the seroprevalence of HBV
from 30.8 % to 10 % for the last three years (Fig. 1).
Discussion
The limitations of the majority of serological and DNA
tests were also considerable to the test kit used by this
study. Determination of HBsAg alone may not exactly
measure the overall prevalence of HBV infection in a
given population as other viral co-infections such as
HIV or HCV are indicators of the total infection rate.
The carrier state of HBsAg is defined as persistence of
this antigen in the blood for over 6 months. Thus, a sin-
gle determination of HBsAg may not be the ideal way of
defining the carrier state among study subjects.
Keeping the limitations, the overall seroprevalence of
HBsAg in this study was 21.2 %% of which 12.7 % were
males and 8.5 % were females. This finding was lower
than reports from Logos, Nigeria, 25.7 % [12], and
Jimma, Ethiopia, 24.2 % [22]. However, our finding was
higher than reports from countries like in Central Africa
Republic 15.5 % [26], Kenya 8.8 % [27], Nigeria 7.1 %
[28], and two studies in India reporting, 4.9 % [29] and
0.61 % [30]. Moreover it was higher than two preva-
lences 3.4 % [21] and 9.8 % from Pakistan [31], and one
Palestin syudy 8.1 % [32]. This difference may be due to
geographical variation, genetic difference; immunity,
other socioeconomic characteristics and sample size
variation also may contribute to this difference.
The finding of this study was also higher than any of
the cross-sectional studies conducted in Ethiopia, Addis
Ababa, 7 % [23], Southwest, 3.7 % [33], and Northern,
6.2 % [34]. All are lower than our finding due to may be
sample size difference, geographical variation, method of
detection or this study was done on suspected patients,
that increase rate of positivity.
The sex based seroprevalence of HBsAg was higher in
males-12.7 % than in females-8.5 %. This is in line with
reports from Pakistan −12.7 % in males and 5.8 % in fe-
males [22], from Jimma University, Ethiopia – 22.6 % in
males and 1.6 % in females [24], from Palestine – 6.5 %
in males and 1.6 % in females [32]. In contrast a study
from Kenya reported that the prevalence was higher in
females 9.4 % [27] while another study in Ethiopia re-
ported no difference among males and females [16].
The year to year decrement in the prevalence of HBsAg
observed in our study may indicate time to time incre-
ment in awareness in the community and advancement of
Health services. However; one study showed that hepatitis
Table 4 Seroprevalence of HBV from Jan 2012 – Dec 2014 in terms of sex of the patients at THMH, Sekota, Northern Ethiopia, 2015
Year Sex HBV Total
Male Female
Positive Negative Total Positive Negative Total Positive Negative
2012 38 (19.2 %) 83 (41.9 %) 121 (61.1 %) 23 (11.6 %) 54 (27.3 %) 77 (38.9 %) 61 (30.8 %) 137 (69.2 % 198 (100 %)
2013 15 (11.2 %) 61 (45.5 %) 76 (56.7 %) 11 (8.2 %) 47 (35.1 %) 58 (43.3 %) 26 (19.4 %) 108 (80.6 %) 134 (100 %)
2014 8 (5.3 %) 62 (41.3 %) 70 (46.7 %) 7 (4.8 %) 73 (48.7 %) 80 (53.33 %) 15 (10 %) 135 (90 %) 150 (100 %)
Total 61 (22.8 %) 206 (77.2 %) 267 (100 %) 41 (19.1 %) 174 (80.9 %) 215 (100 %) 102 (21.2 %) 380 (78.8 %) 482 (100 %)





Positive Negative Total Positive Negative Total Positive Negative
0–14 7 (1.4 %) 34 (7.1 %) 41 (8.5 %) 4 (0.8 %) 14 (2.90 %) 18 (3.7 %) 11 (2.3 %) 48 (9.9 %) 59 (12.2 %)
15-45 40 (8.3 %) 120 (24.9 %) 160 (33.2 %) 29 (6.0 %) 138 (28.6 %) 167 (34.6 %) 69 (14.3 %) 258 (53.5 %) 327 (67.8 %)
>45 14 (2.9 %) 52 (10.8 %) 66 (13.7 %) 8 (1.6 %) 22 (4.6 %) 30 (6.2 %) 22 (4.7 %) 74 (13.3 %) 96 (19.9 %)
Total 61 (12.7 %) 206 (42.7 %) 267 (55.4 %) 41 (8.5 %) 174 (36.1 %) 215 (44.6) 102 (21.2 %) 380 (78.8 %) 482 (100 %)
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medications are not affordable to the majority of the
population and the situation is not changed. Since
there is no public funding/subsidy for hepatitis infec-
tions in Ethiopia, payment is generally out-of-pocket
by the individual. Some anti-retroviral drugs given for
HIV act against HBV but the government policy in
Ethiopia restricts the use of these drugs for the treat-
ment of HBV for fear of the emergence of drug re-
sistance. Hence, for mono-infected cases of chronic
HBV, the drugs (tenofovir, lamivudine) are not readily
available either in the public or private sectors in
Ethiopia. However, HIV–HBV co-infected patients re-
ceive free treatment at HIV clinics [35].
Therefore, further investigation of HBV with other
coifections and possible risk factors using large sam-
ple with a longer period of study involving control
groups should be carried out in order to get more
ideal information.
Conclusion
Infection induced hepatitis is a severe cause of mortality
and morbidity especially in developing countries. In this
study the seroprevalence of HBsAg was 21.5 % and it
was higher in males than in females. The yearly preva-
lence decreases from 2012–2014. However; the study in-
dicates that HBV infection is still a public health
problem which should be among the prioritized health
problems in the country.
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